Vapotherm Inc
F:VA21
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vapotherm Inc
Cash from Operating Activities
Vapotherm Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vapotherm Inc
F:VA21
|
Cash from Operating Activities
-$24.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash from Operating Activities
$4.5B
|
CAGR 3-Years
44%
|
CAGR 5-Years
25%
|
CAGR 10-Years
21%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash from Operating Activities
$1.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash from Operating Activities
$5B
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash from Operating Activities
$9.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash from Operating Activities
$3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
Vapotherm Inc
Glance View
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 510 full-time employees. The company went IPO on 2018-11-14. The firm is focused on the care of patients of all ages suffering from the respiratory distress often associated with complex lung diseases, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company offers four versions of its Precision Flow systems, which includes Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its digital solutions are focused on at home patient monitoring. The firm also provides various clinical solutions.
See Also
What is Vapotherm Inc's Cash from Operating Activities?
Cash from Operating Activities
-24.3m
USD
Based on the financial report for Dec 31, 2023, Vapotherm Inc's Cash from Operating Activities amounts to -24.3m USD.
What is Vapotherm Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
9%
Over the last year, the Cash from Operating Activities growth was 70%. The average annual Cash from Operating Activities growth rates for Vapotherm Inc have been 15% over the past three years , 9% over the past five years .
